Vitamin D levels, microvascular complications, and mortality in type 1 diabetes

Diabetes Care

Volumn 34, Issue 5, 2011, Pages 1081-1085

  Joergensen, Christel ^a   Hovind, Peter ^a,b   Schmedes, Anne ^c   Parving, Hans Henrik ^d   Rossing, Peter ^a  

^a STENO DIABETES CENTER   (Denmark)

^b GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^c LILLEBAELT HOSPITAL   (Denmark)

^d University of Copenhagen   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; CALCIFEDIOL; HEMOGLOBIN A1C;

25 HYDROXYVITAMIN D3 BLOOD LEVEL; ADOLESCENT; ADULT; ARTICLE; CARDIOVASCULAR RISK; CHILD; COHORT ANALYSIS; DIABETIC MICROANGIOPATHY; DIABETIC RETINOPATHY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FOLLOW UP; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; MICROALBUMINURIA; MORTALITY; OBSERVATIONAL STUDY; PREDICTIVE VALUE; PRESCHOOL CHILD; PROGNOSIS; PROLIFERATIVE RETINOPATHY; PROSPECTIVE STUDY; SCHOOL CHILD; TANDEM MASS SPECTROMETRY; URINARY ALBUMIN EXCRETION RATE; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY;

ADOLESCENT; ADULT; ALBUMINURIA; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; MALE; PROSPECTIVE STUDIES; TANDEM MASS SPECTROMETRY; VITAMIN D; YOUNG ADULT;

EID: 79956123653     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc10-2459     Document Type: Article

References (25)

1. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266-281
2. Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 2008;168:1629-1637
3. Joergensen C, Gall MA, Schmedes A, Tarnow L, Parving H-H, Rossing P. Vitamin D levels and mortality in type 2 diabetes. Diabetes Care 2010;33:2238-2243
4. Rossing P, Hougaard P, Borch-Johnsen K, Parving H-H. Predictors of mortality in insulin dependent diabetes: 10 year observational follow up study. BMJ 1996; 313:779-784 (Pubitemid 26326878)
5. Parving H-H, Mauer M, Ritz E. Diabetic nephropathy. In Brenner & Rector's The Kidney. 8th ed. Brenner BM, Ed. Boston, WB Saunders, 2008, p. 1265-1298
6. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986
7. de Boer IH, Ioannou GN, Kestenbaum B, Brunzell JD, Weiss NS. 25-Hydroxyvitamin D levels and albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis 2007;50:69-77 (Pubitemid 46962855)
8. Alborzi P, Patel NA, Peterson C, et al. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension 2008;52:249-255
9. Schwarz U, Amann K, Orth SR, Simonaviciene A, Wessels S, Ritz E. Effect of 1,25 (OH)2 vitamin D3 on glomerulosclerosis in subtotally nephrectomized rats. Kidney Int 1998;53:1696-1705
10. Agarwal R, Acharya M, Tian J, et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 2005;68:2823-2828 (Pubitemid 43251029)
11. de Zeeuw D, Agarwal R, Amdahl M, et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 2010;376:1543-1551
12. Hovind P, Tarnow L, Rossing K, et al. Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes. Diabetes Care 2003;26:1258-1264 (Pubitemid 36929282)
13. Viberti GC, Mogensen CE, Groop LC, Pauls JF; European Microalbuminuria Captopril Study Group. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. JAMA 1994;271:275-279
14. Parving H-H, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-878
15. Hollis BW. Measuring 25-hydroxyvitamin D in a clinical environment: challenges and needs (Abstract). Am J Clin Nutr 2008;88:507S-510S
16. Ravani P, Malberti F, Tripepi G, et al. Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int 2009;75:88-95
17. Wolf M, Shah A, Gutierrez O, et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007;72:1004-1013 (Pubitemid 47530570)
18. Kull M Jr, Kallikorm R, Tamm A, Lember M. Seasonal variance of 25-(OH) vitamin D in the general population of Estonia, a Northern European country (Abstract). BMC Public Health 2009;9:22
19. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the reninangiotensin system. J Clin Invest 2002;110:229-238
20. Xiang W, Kong J, Chen S, et al. Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab 2005;288:E125-E132 (Pubitemid 40023798)
21. Zehnder D, Quinkler M, Eardley KS, et al. Reduction of the vitamin D hormonal systemin kidney disease is associatedwith increased renal inflammation. Kidney Int 2008;74:1343-1353
22. Chonchol M, Cigolini M, Targher G. Association between 25-hydroxyvitamin D deficiency and cardiovascular disease in type 2 diabetic patients with mild kidney dysfunction. Nephrol Dial Transplant 2008;23:269-274 (Pubitemid 351767364)
23. Oh J, Weng S, Felton SK, et al. 1,25(OH) 2 vitamin D inhibits foam cell formation and suppresses macrophage cholesterol uptake in patients with type 2 diabetes mellitus. Circulation 2009;120:687-698
24. Hovind P, Tarnow L, Rossing P, et al. Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study (Abstract). BMJ 2004;328:1105
25. Suzuki A, Kotake M, Ono Y, et al. Hypovitaminosis D in type 2 diabetes mellitus: Association with microvascular complications and type of treatment. Endocr J 2006;53:503-510 (Pubitemid 44351501)